Stock Events

Nascent Biotech 

$0.09
8
+$0+4.44% Wednesday 20:28

Statistics

Day High
0.09
Day Low
0.09
52W High
0.28
52W Low
0.03
Volume
8,055
Avg. Volume
110,853
Mkt Cap
20.75M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

10NovConfirmed
Q4 2020
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.01
-0
0
0.01
Expected EPS
N/A
Actual EPS
-0.0012

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NBIO. It's not an investment recommendation.

About

Agricultural Commodities/Milling
Process Industries
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company has a research collaboration agreement with Manhattan BioSolutions, Inc. to initiate a vaccine program for the prevention of COVID-19 or other viral infections; and a collaboration with Hoag Family Cancer Institute and Pickup Family Neurosciences Institute for the testing of antibody brain cancer drug. The company is based in San Diego, California.
Show more...
CEO
Country
US
ISIN
US63108Q1013

Listings